Skip to content
BiologicalX

Comparison

Hexarelin vs Low-Dose Naltrexone

Side-by-side of Hexarelin and Low-Dose Naltrexone. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Hexarelin

  • Synthetic hexapeptide GHS-R1a agonist; produces the largest acute GH pulse of the synthetic GHRP class
  • Independent CD36 signaling produces cardioprotective effects in rodent ischemia models, GH-independent
  • Pronounced tachyphylaxis: GH response attenuates over 2 to 4 weeks of daily dosing
  • More cortisol and prolactin elevation than GHRP-2 or ipamorelin
  • Anecdotal protocols use 100 to 200 mcg subcutaneously 1 to 2 times daily for 2 to 4 week pulses
  • Banned by WADA under S2; advanced through phase 2 trials but never reached registration

Low-Dose Naltrexone

  • Off-label use at 1.5 to 4.5 mg, roughly one-tenth the FDA-approved 50 mg addiction-treatment dose
  • Proposed mechanisms include brief opioid receptor blockade triggering rebound endogenous opioid release, plus TLR4 antagonism
  • Compounded prescription only; insurance rarely covers; cash prices 20 to 80 USD per month
  • Younger 2013 reported ~30% pain reduction in fibromyalgia at 4.5 mg in a small crossover trial
  • Smith 2011 reported endoscopic improvement in active Crohn's disease (n=40 placebo-controlled)
  • Vivid dreams affect 20 to 40% in first 2 weeks; manageable by switching to morning dosing

Side-by-side

Attribute Hexarelin Low-Dose Naltrexone
Category peptide pharmaceutical
Also known as Examorelin, EP-23905, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 LDN, naltrexone (low dose)
Half-life (hr) 1 4
Typical dose (mg) 0.1 4.5
Dosing frequency 1-2x daily once daily, typically at bedtime
Routes subcutaneous, intranasal, intravenous oral
Onset (hr) 0.25 1
Peak (hr) 0.5 1.5
Molecular weight 887.04 341.4
Molecular formula C47H58N12O6 C20H23NO4
Mechanism Hexapeptide agonist of GHS-R1a producing acute GH release with cortisol and prolactin co-elevation. Independent CD36 binding produces GH-independent cardioprotective signaling in preclinical models. Brief mu-opioid receptor antagonism proposed to trigger compensatory upregulation of endogenous opioids; secondary TLR4 antagonism on microglia and immune cells contributes to anti-inflammatory effect.
Legal status Not FDA approved; advanced through phase 2 trials in EU but never registered; research-use-only grey market; banned by WADA Off-label compounded prescription (naltrexone is FDA approved for opioid and alcohol use disorder at 50 mg)
WADA status banned allowed
DEA / Rx Not scheduled (research chemical) Rx only (not a controlled substance)
Pregnancy Insufficient data; not recommended Insufficient data; not routinely recommended
CAS 140703-51-1 16590-41-3
PubChem CID 3037387 5360515
Wikidata Q5743550 Q426444

Safety profile

Hexarelin

Common side effects

  • water retention
  • vivid dreams
  • head pressure or flushing
  • transient lethargy
  • tingling at injection site
  • moderate hunger

Contraindications

  • pregnancy
  • active malignancy
  • history of pituitary tumor
  • uncontrolled diabetes
  • prolactin-sensitive states

Interactions

  • CJC-1295: synergistic GH release; accelerates tachyphylaxis if used continuously(minor)
  • sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
  • insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
  • corticosteroids: amplify cortisol load; blunt GH response(moderate)

Low-Dose Naltrexone

Common side effects

  • vivid dreams
  • sleep disruption
  • headache
  • mild GI upset
  • fatigue (early)

Contraindications

  • concurrent opioid use
  • acute hepatitis or liver failure
  • opioid dependence
  • pregnancy (insufficient data)

Interactions

  • opioid analgesics (oxycodone, morphine, codeine): blocks analgesic effect; precipitates withdrawal in dependent users(major)
  • tramadol: blocks opioid component of analgesia(major)
  • thyroid hormone replacement: may alter dose requirements after immune modulation; monitor TSH(minor)

Which Should You Take?

Low-Dose Naltrexone comes out ahead for most readers on the criteria we weight: 2 catalogued goals, prescription-only, oral dosing, with a Tier-A outcome catalogued. Hexarelin is the right call when one of the conditionals below applies.

Edge case: If you cannot self-administer injections, Low-Dose Naltrexone is the only oral option in this pair.

Default choice: Low-Dose Naltrexone. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Hexarelin only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Hexarelin and Low-Dose Naltrexone?

Hexarelin and Low-Dose Naltrexone differ in category (peptide vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Hexarelin or Low-Dose Naltrexone?

Hexarelin half-life is 1 hours; Low-Dose Naltrexone half-life is 4 hours.

Can you stack Hexarelin with Low-Dose Naltrexone?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper